Literature DB >> 16178870

Mechanisms dependent on tryptophan catabolism regulate immune responses in primary Sjögren's syndrome.

M Pertovaara1, A Raitala, H Uusitalo, J Pukander, H Helin, S S Oja, M Hurme.   

Abstract

To investigate the possible role of tryptophan metabolism in immune regulation of primary Sjögren's syndrome (pSS) the serum concentrations of tryptophan and its metabolite kynurenine were measured by reverse-phase high-performance liquid chromatography (HPLC) in 103 patients with pSS, 56 patients with sicca symptoms and 309 healthy blood donors. The kynurenine per tryptophan ratio (kyn/trp), which reflects the activity of the indoleamine-pyrrole 2,3-dioxygenase (IDO) enzyme involved in tryptophan catabolism, was calculated. Both female and male patients with pSS had significantly higher serum kynurenine concentrations and kyn/trp than subjects with sicca symptoms or healthy blood donors. The median (quartile range) concentration of kynurenine in female patients with pSS was 2.41 micromol/l (1.86-3.26) compared with 1.85 micromol/l (1.58-2.38, P < 0.0001) in subjects with sicca symptoms and 1.96 micromol/l (1.65-2.27, P < 0.0001) in healthy blood donors. Their kyn/trp x 1000 was 34.0 (25.1-44.3) compared with 25.3 (21.1-31.5, P < 0.0001) in subjects with sicca symptoms and 24.3 (21.0-28.9, P < 0.0001) in healthy blood donors. Female pSS patients with high IDO activity (kyn/trp x 1000 > or = 34.0) had significantly higher ESR, serum C-reactive protein, serum IgA and serum beta-2 microglobulin concentrations as well as higher serum creatinine levels, and they had positive antinuclear antibodies more frequently and presented with more American-European consensus group criteria than those with low IDO activity (kyn/trp x 1000 < 34.0). These data suggest that mechanisms dependent on tryptophan catabolism regulate immune responses in pSS. Tryptophan degradation is enhanced in patients with pSS, and high IDO activity is associated with severity of pSS.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16178870      PMCID: PMC1809473          DOI: 10.1111/j.1365-2249.2005.02889.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  22 in total

1.  More rapid method for simultaneous measurement of tryptophan and kynurenine by HPLC.

Authors:  Andreas Laich; Gabriele Neurauter; Bernhard Widner; Dietmar Fuchs
Journal:  Clin Chem       Date:  2002-03       Impact factor: 8.327

Review 2.  Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group.

Authors:  C Vitali; S Bombardieri; R Jonsson; H M Moutsopoulos; E L Alexander; S E Carsons; T E Daniels; P C Fox; R I Fox; S S Kassan; S R Pillemer; N Talal; M H Weisman
Journal:  Ann Rheum Dis       Date:  2002-06       Impact factor: 19.103

Review 3.  Tryptophan catabolism and regulation of adaptive immunity.

Authors:  Andrew L Mellor; David H Munn
Journal:  J Immunol       Date:  2003-06-15       Impact factor: 5.422

4.  A longitudinal cohort study of Finnish patients with primary Sjögren's syndrome: clinical, immunological, and epidemiological aspects.

Authors:  M Pertovaara; E Pukkala; P Laippala; A Miettinen; A Pasternack
Journal:  Ann Rheum Dis       Date:  2001-05       Impact factor: 19.103

Review 5.  Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation?

Authors:  A L Mellor; D H Munn
Journal:  Immunol Today       Date:  1999-10

6.  Genetic association between interleukin-10 promoter region polymorphisms and primary Sjögren's syndrome.

Authors:  J Hulkkonen; M Pertovaara; J Antonen; N Lahdenpohja; A Pasternack; M Hurme
Journal:  Arthritis Rheum       Date:  2001-01

7.  Kynurenine and neopterin in chronic glomerulonephritis.

Authors:  A Martinsons; V Rudzite; V Groma; O Bratslavska; B Widner; D Fuchs
Journal:  Adv Exp Med Biol       Date:  1999       Impact factor: 2.622

8.  The role of interleukin-10 promoter polymorphisms in the clinical expression of primary Sjögren's syndrome.

Authors:  J Font; M García-Carrasco; M Ramos-Casals; A I Aldea; R Cervera; M Ingelmo; J Vives; J Yagüe
Journal:  Rheumatology (Oxford)       Date:  2002-09       Impact factor: 7.580

9.  Association of transforming growth factor beta1 and tumor necrosis factor alpha polymorphisms with anti-SSB/La antibody secretion in patients with primary Sjögren's syndrome.

Authors:  Jacques-Eric Gottenberg; Marc Busson; Pascale Loiseau; Monique Dourche; Julien Cohen-Solal; Virginia Lepage; Dominique Charron; Corinne Miceli; Jean Sibilia; Xavier Mariette
Journal:  Arthritis Rheum       Date:  2004-02

Review 10.  The genetics of primary Sjögren's syndrome.

Authors:  Amr H Sawalha; Robyn Potts; Wendi R Schmid; R Hal Scofield; John B Harley
Journal:  Curr Rheumatol Rep       Date:  2003-08       Impact factor: 4.592

View more
  14 in total

Review 1.  Lacritin and the tear proteome as natural replacement therapy for dry eye.

Authors:  Roy Karnati; Diane E Laurie; Gordon W Laurie
Journal:  Exp Eye Res       Date:  2013-06-12       Impact factor: 3.467

2.  The role of B7 family costimulatory molecules and indoleamine 2,3-dioxygenase in primary Sjögren's syndrome and systemic sclerosis.

Authors:  Nóra Legány; László Berta; László Kovács; Attila Balog; Gergely Toldi
Journal:  Immunol Res       Date:  2017-06       Impact factor: 2.829

3.  The activity of the immunoregulatory enzyme indoleamine 2,3-dioxygenase is decreased in smokers.

Authors:  M Pertovaara; M Heliövaara; A Raitala; S S Oja; P Knekt; M Hurme
Journal:  Clin Exp Immunol       Date:  2006-09       Impact factor: 4.330

4.  Clinical significance of simultaneous determination of serum tryptophan and tyrosine in patients with lung cancer.

Authors:  Ya-Ping Ren; Ai-Guo Tang; Qian-Xuan Zhou; Zhong-Yuan Xiang
Journal:  J Clin Lab Anal       Date:  2011       Impact factor: 2.352

Review 5.  Targeting the immunoregulatory indoleamine 2,3 dioxygenase pathway in immunotherapy.

Authors:  Burles A Johnson; Babak Baban; Andrew L Mellor
Journal:  Immunotherapy       Date:  2009-07       Impact factor: 4.196

6.  Indoleamine 2,3-dioxygenase activity is increased in patients with systemic lupus erythematosus and predicts disease activation in the sunny season.

Authors:  M Pertovaara; T Hasan; A Raitala; S S Oja; U Yli-Kerttula; M Korpela; M Hurme
Journal:  Clin Exp Immunol       Date:  2007-08-17       Impact factor: 4.330

7.  Indoleamine 2,3-dioxygenase enzyme activity correlates with risk factors for atherosclerosis: the Cardiovascular Risk in Young Finns Study.

Authors:  M Pertovaara; A Raitala; M Juonala; T Lehtimäki; H Huhtala; S S Oja; E Jokinen; J S A Viikari; O T Raitakari; M Hurme
Journal:  Clin Exp Immunol       Date:  2007-04       Impact factor: 4.330

8.  Quantification of IDO1 enzyme activity in normal and malignant tissues.

Authors:  Lijie Zhai; Erik Ladomersky; April Bell; Corey Dussold; Krislyn Cardoza; Jun Qian; Kristen L Lauing; Derek A Wainwright
Journal:  Methods Enzymol       Date:  2019-07-24       Impact factor: 1.600

9.  Accelerated tryptophan degradation predicts poor survival in trauma and sepsis patients.

Authors:  Martin Ploder; Andreas Spittler; Katharina Kurz; Gabriele Neurauter; Linda E Pelinka; Erich Roth; Dietmar Fuchs
Journal:  Int J Tryptophan Res       Date:  2010-06-10

10.  Peripheral regulatory cells immunophenotyping in kidney transplant recipients with different clinical profiles: a cross-sectional study.

Authors:  Janette Furuzawa-Carballeda; Guadalupe Lima; Perla Simancas; Dolores Ramos-Bello; Margaret Simancas; Ian C Bostock; Mario Vilatobá; Bernardo Gabilondo; Julio Granados; Luis Morales-Buenrostro; Josefina Alberú; Luis Llorente
Journal:  J Transplant       Date:  2012-11-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.